Atopic dermatitis laboratory findings

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Shalinder Singh, M.B.B.S.[2]

Overview

There diagnosis of atopic dermatitis remains clinical as there is no reliable bio-marker that can differentiate atopic dermatitis from other skin diseases.

Laboratory Findings

There are no reliable diagnostic laboratory findings associated with atopic dermatitis.
The most common laborotory finding in atopic dermatitis is an elevated total and/or allergen-specific serum IgE level, which is not present in about 20% of affected individuals.^[1]
Monitoring of IgE levels is not recommended for the assessment of atopic dermatitis severity.
Higher serum levels of some of the new biomarkers using the SCORing Atopic Dermatitis (SCORAD) index and other severity scales:^[2]^[3]^[4]^[5]^[6]^[7]^[8]
- Serum levels of CD30
- Macrophage-derived chemoattractant (MDC)
- Interleukins (IL)-12
- Interleukins (IL)-16
- Interleukins (IL)-18
- Interleukins (IL)-31
- Thymus and activation-regulated chemokine (TARC)

References

↑ Kabashima K (April 2013). “New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity”. J. Dermatol. Sci. 70 (1): 3–11. doi:10.1016/j.jdermsci.2013.02.001. PMID 23473856.
↑ Aral M, Arican O, Gul M, Sasmaz S, Kocturk SA, Kastal U, Ekerbicer HC (2006). “The relationship between serum levels of total IgE, IL-18, IL-12, IFN-gamma and disease severity in children with atopic dermatitis”. Mediators Inflamm. 2006 (4): 73098. doi:10.1155/MI/2006/73098. PMC 1618943. PMID 17047294.
↑ Di Lorenzo G, Gangemi S, Merendino RA, Minciullo PL, Cannavò SP, Martinelli N, Mansueto P, Rini GB, Corrocher R, Pacor ML (April 2003). “Serum levels of soluble CD30 in adult patients affected by atopic dermatitis and its relation to age, duration of disease and Scoring Atopic Dermatitis index”. Mediators Inflamm. 12 (2): 123–5. doi:10.1080/0962935031000097736. PMC 1781600. PMID 12775363.
↑ El Mongy S, Metwaly SS, Arafat MS, Hady HA (2008). “Serum levels of soluble CD30 in patients with atopic dermatitis: correlations with age, disease duration and severity”. Egypt J Immunol. 15 (1): 123–9. PMID 20306677.
↑ Ezzat MH, Hasan ZE, Shaheen KY (March 2011). “Serum measurement of interleukin-31 (IL-31) in paediatric atopic dermatitis: elevated levels correlate with severity scoring”. J Eur Acad Dermatol Venereol. 25 (3): 334–9. doi:10.1111/j.1468-3083.2010.03794.x. PMID 21294778.
↑ Jahnz-Rozyk K, Targowski T, Paluchowska E, Owczarek W, Kucharczyk A (May 2005). “Serum thymus and activation-regulated chemokine, macrophage-derived chemokine and eotaxin as markers of severity of atopic dermatitis”. Allergy. 60 (5): 685–8. doi:10.1111/j.1398-9995.2005.00774.x. PMID 15813816.
↑ Nakazato J, Kishida M, Kuroiwa R, Fujiwara J, Shimoda M, Shinomiya N (November 2008). “Serum levels of Th2 chemokines, CCL17, CCL22, and CCL27, were the important markers of severity in infantile atopic dermatitis”. Pediatr Allergy Immunol. 19 (7): 605–13. doi:10.1111/j.1399-3038.2007.00692.x. PMID 18266834.
↑ Ständer, Sonja; Ropper, Allan H. (2021). “Atopic Dermatitis”. New England Journal of Medicine. 384 (12): 1136–1143. doi:10.1056/NEJMra2023911. ISSN 0028-4793.

[pmid234738562-1] Kabashima K (April 2013). “New concept of the pathogenesis of atopic dermatitis: interplay among the barrier, allergy, and pruritus as a trinity”. J. Dermatol. Sci. 70 (1): 3–11. doi:10.1016/j.jdermsci.2013.02.001. PMID 23473856.

[pmid170472942-2] Aral M, Arican O, Gul M, Sasmaz S, Kocturk SA, Kastal U, Ekerbicer HC (2006). “The relationship between serum levels of total IgE, IL-18, IL-12, IFN-gamma and disease severity in children with atopic dermatitis”. Mediators Inflamm. 2006 (4): 73098. doi:10.1155/MI/2006/73098. PMC 1618943. PMID 17047294.

[pmid127753632-3] Di Lorenzo G, Gangemi S, Merendino RA, Minciullo PL, Cannavò SP, Martinelli N, Mansueto P, Rini GB, Corrocher R, Pacor ML (April 2003). “Serum levels of soluble CD30 in adult patients affected by atopic dermatitis and its relation to age, duration of disease and Scoring Atopic Dermatitis index”. Mediators Inflamm. 12 (2): 123–5. doi:10.1080/0962935031000097736. PMC 1781600. PMID 12775363.

[pmid20306677-4] El Mongy S, Metwaly SS, Arafat MS, Hady HA (2008). “Serum levels of soluble CD30 in patients with atopic dermatitis: correlations with age, disease duration and severity”. Egypt J Immunol. 15 (1): 123–9. PMID 20306677.

[pmid21294778-5] Ezzat MH, Hasan ZE, Shaheen KY (March 2011). “Serum measurement of interleukin-31 (IL-31) in paediatric atopic dermatitis: elevated levels correlate with severity scoring”. J Eur Acad Dermatol Venereol. 25 (3): 334–9. doi:10.1111/j.1468-3083.2010.03794.x. PMID 21294778.

[pmid15813816-6] Jahnz-Rozyk K, Targowski T, Paluchowska E, Owczarek W, Kucharczyk A (May 2005). “Serum thymus and activation-regulated chemokine, macrophage-derived chemokine and eotaxin as markers of severity of atopic dermatitis”. Allergy. 60 (5): 685–8. doi:10.1111/j.1398-9995.2005.00774.x. PMID 15813816.

[pmid18266834-7] Nakazato J, Kishida M, Kuroiwa R, Fujiwara J, Shimoda M, Shinomiya N (November 2008). “Serum levels of Th2 chemokines, CCL17, CCL22, and CCL27, were the important markers of severity in infantile atopic dermatitis”. Pediatr Allergy Immunol. 19 (7): 605–13. doi:10.1111/j.1399-3038.2007.00692.x. PMID 18266834.

[StänderRopper2021-8] Ständer, Sonja; Ropper, Allan H. (2021). “Atopic Dermatitis”. New England Journal of Medicine. 384 (12): 1136–1143. doi:10.1056/NEJMra2023911. ISSN 0028-4793.

[1]

[2]

[3]

[4]

[5]

[6]

[7]

[8]